CJC-1295 & Ipamorelin Dosage Calculator
Work out your CJC-1295 (no DAC) / Ipamorelin blend concentration, draw volume, and syringe units from your vial size, diluent, and target per-peptide dose — built on the same reconstitution math as the main Peptide Calculator.
How CJC-1295 & Ipamorelin reconstitution math works
Both CJC-1295 (no DAC) and Ipamorelin ship as freeze-dried powder and are almost always sold pre-blended in a single multi-dose vial. Once bacteriostatic or sterile water is added, each peptide disperses evenly through that liquid — so the strength of the solution for each peptide depends on three numbers: how many total milligrams are in the vial, what fraction of that total is each peptide, and how much diluent you added. The general reconstitution formula is the same one covered on the main Peptide Calculator; this tool simply applies it twice — once per peptide in the blend.
volume to draw (mL) = target per-peptide dose (mg) ÷ per-peptide concentration (mg/mL)
syringe units = volume to draw (mL) × syringe scale (100 for U-100, 40 for U-40)
Worked example
A 10 mg blend vial (5 mg CJC-1295 no DAC + 5 mg Ipamorelin, a 1:1 split) mixed with 2 mL of bacteriostatic water gives each peptide a concentration of 2.5 mg/mL. To hit a 200 mcg (0.2 mg) per-peptide target, you’d draw 0.08 mL — which reads as 8 units on a U-100 insulin syringe, delivering 200 mcg of CJC-1295 and 200 mcg of Ipamorelin in the same draw. That single vial covers roughly 25 daily doses of that pair before it’s empty.
CJC-1295 & Ipamorelin dosing by experience level
Because neither peptide carries an FDA-approved label or dosing schedule, the ranges below reflect what’s consistently documented across peptide-research protocols and community reconstitution guides — not a clinical recommendation. Most protocols start low and titrate upward over the first one to two weeks.
| Level | CJC-1295 (no DAC) | Ipamorelin | Typical frequency |
|---|---|---|---|
| Beginner | 100 mcg | 100 mcg | Once daily, before bed |
| Intermediate | 200 mcg | 200 mcg | Once daily, or 5 days on / 2 off |
| Advanced | 300 mcg | 300 mcg | Once or twice daily, empty stomach |
| CJC-1295 with DAC variant | 2 mg | 200 mcg (dosed separately, nightly) | CJC-DAC: 1–2×/week · Ipamorelin: daily |
The DAC-modified form of CJC-1295 has a multi-day half-life and is dosed on a completely different schedule from the no-DAC form used in most blend vials — the two aren’t interchangeable milligram-for-milligram. If you’re working with a GHRH-class peptide that does have an FDA-approved dosing label, the tesamorelin dosage calculator covers that fixed-dose protocol.
Mechanism, briefly
CJC-1295 (no DAC, also called Mod GRF 1-29) is a synthetic analog of growth hormone-releasing hormone (GHRH). It binds the GHRH receptor on pituitary somatotroph cells, prompting the pituitary to synthesize and release its own growth hormone. Ipamorelin works through a different pathway: it’s a selective pentapeptide agonist of the ghrelin (growth hormone secretagogue) receptor, first characterized by Raun and colleagues in 1998, and it triggers an acute GH pulse without the meaningful rise in ACTH, cortisol, or prolactin seen with older growth hormone-releasing peptides. Paired together, the GHRH-receptor signal and the ghrelin-receptor signal act on the same pituitary cells through separate mechanisms, which is why the combination is described in the pharmacology literature as synergistic rather than simply additive.
Timing matters for this specific pairing: CJC-1295 without DAC has a half-life of roughly 30 minutes, closely matching Ipamorelin’s roughly 2-hour clearance. That similarity is what preserves the body’s natural pulsatile GH release pattern. The DAC-modified version of CJC-1295 behaves very differently — its half-life extends to 5.8–8.1 days according to the original human pharmacokinetic trial, producing sustained rather than pulsatile GHRH stimulation, which is why it’s dosed on a weekly schedule instead of nightly alongside Ipamorelin.
Commonly researched alongside CJC-1295 & Ipamorelin
This GH-secretagogue pairing is frequently run alongside other peptides targeting a different research question entirely, each with its own reconstitution math. Researchers layering in soft-tissue recovery work often run the numbers through the BPC-157 dosage calculator separately, since BPC-157 targets tissue repair rather than GH pulsatility and follows its own schedule. For body-composition protocols that pair a GH secretagogue with a GLP-1 agonist, the tirzepatide dosage calculator and retatrutide dosage calculator handle each compound’s own titration schedule independently — stacking mechanisms doesn’t mean stacking the math. And for researchers comparing GHRH analogs directly, the tesamorelin dosage calculator covers the one GHRH-class peptide in this cluster with an actual FDA-approved dosing label.
Frequently asked questions
Community-documented research protocols most commonly range from 100 to 300 mcg of each peptide, injected subcutaneously once daily before bed from a 1:1 blend vial. Neither peptide has an FDA-approved label, so these figures reflect published research and reconstitution guides rather than a clinical dosing standard.
Usually yes. Most retail vials are already pre-blended 1:1, so one draw from that vial delivers both peptides at the same dose in a single injection. If you’re working from two separate single-peptide vials instead, each one needs its own concentration and draw-volume calculation.
The no-DAC form (used in most CJC-1295/Ipamorelin blends) has a roughly 30-minute half-life, which matches Ipamorelin’s pulsatile release pattern for once-daily dosing. The DAC-modified form binds albumin and extends its half-life to 5.8–8.1 days, producing sustained rather than pulsatile GHRH stimulation — it’s dosed once or twice weekly and isn’t typically paired with Ipamorelin in the same nightly injection.
It depends entirely on your concentration. A 10 mg blend vial (5 mg + 5 mg) mixed with 2 mL of diluent works out to 0.08 mL for a 200 mcg per-peptide dose. For any other vial size or diluent volume, divide your target dose in mg by your per-peptide concentration in mg/mL — the calculator above does this instantly.
No — the syringe type only changes how the same liquid volume is displayed. A U-100 and a U-40 insulin syringe both hold 1 mL in the barrel; they just print a different unit scale next to the plunger for that same 1 mL.
No. It performs the arithmetic of concentration and volume based on the numbers you enter. It doesn’t evaluate whether a dose, product, ratio, or schedule is appropriate for any individual, and it isn’t a substitute for guidance from a licensed healthcare provider.
Related peptide calculators
References
- Teichman SL, et al. “Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults.” Journal of Clinical Endocrinology & Metabolism, 2006. doi.org/10.1210/jc.2005-1536
- Raun K, et al. “Ipamorelin, the First Selective Growth Hormone Secretagogue.” European Journal of Endocrinology, 1998. doi.org/10.1530/eje.0.1390552
- Ishida A, et al. “Growth Hormone Secretagogues: History, Mechanism of Action, and Clinical Development.” JCSM Rapid Communications, 2020. onlinelibrary.wiley.com/doi/full/10.1002/rco2.9
- U.S. Food & Drug Administration — Human Drug Compounding